Yuka Nogami
Kawasaki Medical School
8 Papers
5 Citations
Yuka Nogami is an academic researcher from Kawasaki Medical School. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
Junpei Sanada,Atsushi Obata,Yoshiro Fushimi,Tomohiko Kimura,Masatoshi Shimoda,Tomoko Ikeda,Yuka Nogami,Yoshiyuki Obata,Y. Yamasaki,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +12 more
TL;DR: Imeglimin is a new anti-diabetic drug commercialized in Japan (Twymeeg®) and has been drawing much attention in diabetes research area as well as in clinical practice as discussed by the authors .
30
Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Yoshiro Fushimi,Atsushi Obata,Junpei Sanada,Yuka Nogami,Tomoko Ikeda,Yuki Yamasaki,Yoshiyuki Obata,Masashi Shimoda,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +11 more
TL;DR: In this article, the effects of combination therapy of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter 2 (SGLT2) inhibitor on β-cells are investigated.
Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ
Junpei Sanada,Tomohiko Kimura,Masatoshi Shimoda,Yuichiro Iwamoto,Hideyuki Iwamoto,Kazunori Dan,Yoshiro Fushimi,Yukino Katakura,Yuka Nogami,Yoshiko Shirakiya,Y. Yamasaki,Tomoko Ikeda,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +15 more
TL;DR: Imeglimin, a new anti-diabetic drug, exhibits anti-atherosclerotic effects in ApoE KO mice treated with STZ, reducing plaque formation, vascular smooth muscle cell migration, and macrophage infiltration, independent of glycemic and lipid control.
3
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
Yuichiro Iwamoto,Tomohiko Kimura,Kazunori Dan,Hideyuki Iwamoto,Junpei Sanada,Yoshiro Fushimi,Yukino Katakura,Masatoshi Shimoda,Yuka Nogami,Yoshiko Shirakiya,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +13 more
TL;DR: The combination of DPP-4 and SGLT2 inhibitors improves hepatic steatosis through different mechanisms of action, including anti-inflammatory effects and improved glucose metabolism.
2
Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
Tomohiko Kimura,Atsushi Obata,Masashi Shimoda,Hidenori Hirukawa,Yukiko Kanda-Kimura,Yuka Nogami,Kenji Kohara,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +10 more
TL;DR: In this paper, the authors examined whether GLP-1R expression is reduced after long-term exposure to dulaglutide (Dula) in non-diabetic and diabetic mice.